Estamos no ar no ! Saiba mais

LENSAR

LNSR

Valor de mercado US$ 71,3 mi

5,80 USD

-0,23

3,81%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

5,80

0,00

0%

1 dia

-3,81%

5 dias

-9,09%

1 mês

-18,08%

3 meses

2,29%

6 meses

0%

No acumulado do ano

-50,04%

1 ano

-50,93%

5 anos

-22,97%

10 anos

-35,56%

Sobre: LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.

Funcionários: 150

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 25%

Neutro 75%

Negativo 0%

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

Cedar Grove Capital Q3 2026 Portfolio Update

LENSAR Q2 Earnings Call Highlights

LENSAR NASDAQ: LNSR reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter.

LENSAR Q2 Earnings Call Highlights

LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript

LENSAR® Reports Second Quarter 2026 Results and Provides Business Update

10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.

LENSAR® Reports Second Quarter 2026 Results and Provides Business Update

LENSAR Q1 Earnings Call Highlights

LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.

LENSAR Q1 Earnings Call Highlights

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR® Reports First Quarter 2026 Results and Provides Business Update

7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026

LENSAR® Reports First Quarter 2026 Results and Provides Business Update

LENSAR® to Report First Quarter 2026 Results on May 8, 2026

ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026.

LENSAR® to Report First Quarter 2026 Results on May 8, 2026

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025

LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™